• Definium Therapeutics priced an upsized underwritten follow-on offering of 20,588,236 common shares at USD 34 per share.
• Gross proceeds expected to total about USD 700 million, before underwriting discounts, commissions, and offering expenses.
• Underwriters hold a 30-day option to buy up to 3,088,235 additional common shares at the offering price, less discounts and commissions.
• Net proceeds earmarked for R&D, pre-commercialization work for DT120 ODT if approved, working capital, and general corporate purposes.
• Closing targeted for about June 25, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260623369229) on June 24, 2026, and is solely responsible for the information contained therein.